Expert: Totality of Current Data Support the Use of Acalabrutinib in Patients With CLL
In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients
In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed exciting new findings being presented at the American Society of Hematology 2021 Annual Meeting about adverse effects associated with acalabrutinib in patients with chronic lymphocytic leukemia (CLL).
In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients. This formulation is also easier for patients receiving proton pump inhibitors, adding to the convenience and ease of use of acalabrutinib, Andre said.
